07:00 , May 20, 2002 |  BC Week In Review  |  Company News

Dimethaid, Oxo Chemie deal

DMX completed its previously announced acquisition of the 80% of Oxo it did not already own for $37 million (see BioCentury, July 23, 2001). Oxo's Macrokine WF10 tetrachlorodecaoxygen chlorite matrix is in Phase III testing...
07:00 , Jul 23, 2001 |  BC Week In Review  |  Company News

Dimethaid, Oxo Chemie deal

DMX signed a letter of intent to acquire the 80% of Oxo it does not already own for an undisclosed sum. The companies previously had formed a partnership to develop Oxo's Macrokine ( WF10 )...
07:00 , Jul 18, 2001 |  BC Extra  |  Company News

Dimethaid to acquire Oxo Chemie

Drug delivery play Dimethaid (TSE:DMX) signed a letter of intent to acquire the 80% of Oxo Chemie (Fribourg, Switzerland) it does not already own for an undisclosed sum. The companies previously had formed a partnership...
07:00 , Oct 16, 2000 |  BC Week In Review  |  Company News

Iomed management update

Iomed Inc. (IOX), Salt Lake City, Utah   Business: Drug delivery, Autoimmune/Inflammation   Hired: James Laufenberg as VP of sales and marketing, formerly VP of marketing at Oxo Chemie Inc.; Michael Busch as VP of...
07:00 , Aug 14, 2000 |  BC Week In Review  |  Clinical News

Macrokine (WF10): Completed Phase III trial enrollment

WF10 also is in Phase II testing to treat chronic hepatitis C infection (see BioCentury, July 10). The product is marketed in Thailand under the name Immunokine to treat cystitis, proctitis and mucositis following radiation...
07:00 , Aug 8, 2000 |  BC Extra  |  Clinical News

Oxo Chemie completes Phase III enrollment

Oxo Chemie completed enrollment of 240 HIV patients with <=50 CD4 T cells/mm3 in a placebo-controlled North American Phase III trial of its Macrokine ( WF10 ) tetrachlorodecaoxygen chlorite compound to treat late-stage AIDS. The...
07:00 , Jul 10, 2000 |  BC Week In Review  |  Clinical News

Macrokine (WF10): Phase II trial

Oxo Chemie AG. , Fribourg, Switzerland   Product: Macrokine ( WF10 )   Business: Infectious diseases   Therapeutic category: Immune modulation   Target: Macrophages   Description: Tetrachlorodecaoxygen chlorite matrix   Indication: Treat chronic hepatitis C...
07:00 , Jun 29, 2000 |  BC Extra  |  Clinical News

Oxo Chemie starts hepatitis C Phase II

Oxo (Fribourg, Switzerland) began an 80-patient Phase II trial in Germany and Hong Kong of Macrokine to treat chronic active hepatitis C virus. The trial will assess the effect of Macrokine on liver enzymes, necroinflammatory...
08:00 , Mar 20, 2000 |  BC Week In Review  |  Company News

Oxo Chemie Inc. other research news

Oxo Chemie collaborators presented in vitro data showing that exposure of CD14-positive monocytes to WF10 was associated with changes in inflammatory gene expression and inhibition of stimulatory cytokine release. Data were presented at the New...
07:00 , Apr 12, 1999 |  BC Week In Review  |  Clinical News

WF10: Phase III trial update

Oxo Chemie Inc., South San Francisco, Calif.   Product: WF10   Business: Infectious diseases   Therapeutic category: Immune modulation   Target: Macrophages   Description: Tetrachlorodecaoxygen chlorite matrix   Indication: Treat HIV   Status: Oxo, a...